Correction to “Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (CheckMate 648): 29-Month Follow-Up From a Randomized, Open-Label, Phase III Trial”
Kato K, Doki Y, Chau I, et al. Nivolumab Plus Chemotherapy or Ipilimumab Versus Chemotherapy in Patients with Advanced Esophageal Squamous Cell Carcinoma (CheckMate 648): 29-Month Follow-Up from a Randomized, Open-Label, Phase III Trial. Cancer Med. 2024;13(9):e7235, https://doi.org/10.1002/cam4.7235.
In paragraph 11 of the “Results” section, certain data were incorrectly cited in the statement: “Among patients with tumor cell PD-L1 expression <1% treated with nivolumab plus chemotherapy, the median OS by response status at week 18 per BICR was 21.8 months (95% CI 15.7–28.1) for responders versus 9.5 months (95% CI 7.8–12.1) for non-responders (HR 0.42 [95% CI 0.28–0.62]) (Figure S5); 36.0 months (95% CI 22.8 to not estimable) for responders versus 15.0 months (95% CI 11.7–17.2) for non-responders (HR 0.40 [95% CI 0.23–0.71]) with nivolumab plus ipilimumab; and 21.8 months (95% CI 15.7–28.1) for responders versus 9.5 months (95% CI 7.8–12.1) for non-responders (HR 0.42 [95% CI 0.28–0.62]) with chemotherapy alone.”
This should have read: “Among patients with tumor cell PD-L1 expression < 1% treated with nivolumab plus chemotherapy, the median OS by response status at week 18 per BICR was 21.8 months (95% CI 15.7–28.1) for responders versus 9.5 months (95% CI 7.8–12.1) for non-responders (HR 0.42 [95% CI 0.28–0.62]) (Figure S5); 36.0 months (95% CI 22.8 to not estimable) for responders versus 15.0 months (95% CI 11.7–17.2) for non-responders (HR 0.41 [95% CI 0.23–0.71]) with nivolumab plus ipilimumab; and 24.8 months (95% CI 16.4–34.0) for responders versus 11.7 months (95% CI 9.4–13.7) for non-responders (HR 0.44 [95% CI 0.29–0.66]) with chemotherapy alone.”
We apologize for this error.
